Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):: a multicentre, randomised, double-blind, controlled trial

被引:1125
作者
Mann, Johannes F. E. [7 ,8 ]
Schmieder, Roland E. [13 ]
McQueen, Matthew [4 ]
Dyal, Leanne [4 ]
Schumacher, Helmut [14 ]
Pogue, Janice [4 ]
Wang, Xingyu [16 ]
Maggioni, Aldo [6 ]
Budaj, Andrzej [1 ]
Chaithiraphan, Suphachai [2 ]
Dickstein, Kenneth [3 ]
Keltai, Matyas [5 ]
Metsarinne, Kaj [9 ]
Oto, Ali [10 ]
Parkhomenko, Alexander [11 ]
Piegas, Leopoldo S. [12 ]
Svendsen, Tage L. [15 ]
Teo, Koon K. [4 ]
Yusuf, Salim [4 ]
机构
[1] Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland
[2] Chaophya Hosp, Cardiac Ctr, Bangkok, Thailand
[3] Univ Bergen, Stavanger Hosp, Div Cardiol, Bergen, Norway
[4] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
[5] Semmelweis Univ, Gottsegen Gyorgy Hungarian Inst Cardiol, H-1085 Budapest, Hungary
[6] ANMCO Res Ctr, Florence, Italy
[7] Univ Munich, Schwabing Gen Hosp, Munich, Germany
[8] Univ Munich, KfH Kidney Ctr, Munich, Germany
[9] Turku Univ, Cent Hosp, Kantasairaala, Finland
[10] Hacettepe Univ, Ankara, Turkey
[11] Inst Cardiol, Kiev, Ukraine
[12] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil
[13] Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, Erlangen, Germany
[14] Boehringer Ingelheim KG, D-6507 Ingelheim, Germany
[15] Holbaek City Hosp, Holbaek, Denmark
[16] Fu Wai Hosp, Beijing Hypertens League Inst, Beijing, Peoples R China
关键词
D O I
10.1016/S0140-6736(08)61236-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors are known to reduce proteinuria. Their combination might be more effective than either treatment alone, but long-term data for comparative changes in renal function are not available. We investigated the renal effects of ramipril (an ACE inhibitor), telmisartan (an ARB), and their combination in patients aged 55 years or older with established atherosclerotic vascular disease or with diabetes with end-organ damage. Methods The trial ran from 2001 to 2007. After a 3-week run-in period, 25 620 participants were randomly assigned to ramipril 10 mg a day (n=8576), telmisartan 80 mg a day (n=8542), or to a combination of both drugs (n=8502; median follow-up was 56 months), and renal function and proteinuria were measured. The primary renal outcome was a composite of dialysis, doubling of serum creatinine, and death. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00153101. Findings 784 patients permanently discontinued randomised therapy during the trial because of hypotensive symptoms (406 on combination therapy, 149 on ramipril, and 229 on telmisartan). The number of events for the composite primary outcome was similar for telmisartan (n=1147 [13.4%]) and ramipril (1150 [13.5%]; hazard ratio [HR] 1.00, 95% Cl 0 . 92-1. 09), but was increased with combination therapy (1233 [14.5%]; HR 1. 09, 1.01-1.18, p=0.037). The secondary renal outcome, dialysis or doubling of serum creatinine, was similar with telmisartan (189 [2 . 21%]) and ramipril (174 [2.03%]; HR 1.09, 0.89-1.34) and more frequent with combination therapy (212 [2.49%]: HR 1.24, 1.01-1.51, p=0.038). Estimated glomerular filtration rate (eGFR) declined least with ramipril compared with telmisartan (-2-82 [SD 17.2] mL/min/1 . 73 m(2) vs -4.12 [17.4], p<0.0001) or combination therapy (-6.11 [17.9], p<0.0001). The increase in urinary albumin excretion was less with telmisartan (p=0.004) or with combination therapy (p=0.001) than with ramipril. Interpretation In people at high vascular risk, telmisartan's effects on major renal outcomes are similar to ramipril. Although combination therapy reduces proteinuria to a greater extent than monotherapy, overall it worsens major renal outcomes. Funding Boehringer-Ingelheim.
引用
收藏
页码:547 / 553
页数:7
相关论文
共 18 条
[1]   Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine - Is this a cause for concern? [J].
Bakris, GL ;
Weir, MR .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (05) :685-693
[2]   Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [J].
Barnett, AH ;
Bain, SC ;
Bouter, P ;
Karlberg, B ;
Madsbad, S ;
Jervell, J ;
Mustonen, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (19) :1952-1961
[3]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[4]   Effect of inhibitors of the renin-angiotensin system and other anti hypertensive drugs on renal outcomes: systematic review and meta-analysis [J].
Casas, JP ;
Chua, WL ;
Loukogeorgakis, S ;
Vallance, P ;
Smeeth, L ;
Hingorani, AD ;
MacAllister, RJ .
LANCET, 2005, 366 (9502) :2026-2033
[5]   Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals [J].
Gerstein, HC ;
Mann, JFE ;
Yi, QL ;
Zinman, B ;
Dinneen, SF ;
Hoogwerf, B ;
Hallé, JP ;
Young, J ;
Rashkow, A ;
Joyce, C ;
Nawaz, S ;
Yusuf, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (04) :421-426
[6]  
Hilgers KF, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341100
[7]   Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition - A patient-level meta-analysis [J].
Jafar, TH ;
Stark, PC ;
Schmid, CH ;
Landa, M ;
Maschio, G ;
de Jong, PE ;
de Zeeuw, D ;
Shahinfar, S ;
Toto, R ;
Levey, AS .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (04) :244-252
[8]   The COOPERATE trial: a letter of concern [J].
Kunz, Regina ;
Wolbers, Marcel ;
Glass, Tracy ;
Mann, Johannes F. E. .
LANCET, 2008, 371 (9624) :1575-1576
[9]   Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease [J].
Kunz, Regina ;
Friedrich, Chris ;
Wolbers, Marcel ;
Mann, Johannes F. E. .
ANNALS OF INTERNAL MEDICINE, 2008, 148 (01) :30-48
[10]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860